Clinical Trial Update: Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial [Phase 2]

View source ↗

Summary

Phase II randomized trial evaluating tucidinostat with metronomic capecitabine in metastatic triple-negative breast cancer; status and results are currently unk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Tucidinostat (tucidinostat)

Snippet

Sponsor: wang shusen | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN